Patent intelligence · US
US 10517869
Topical brimonidine tartrate ophthalmic solution
Topical brimonidine tartrate ophthalmic solution
Patent details — US 10517869
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 31, 2019
- Expiration
- Dec 26, 2039
- Applicant
- SENTISS PHARMA PRIVATE LIMITED
- Claims
- 2
- CPC classes
- A61K, A61K31/498, A61K47/02, A61K47/186
Quick answer
US 10517869 (Topical brimonidine tartrate ophthalmic solution) is held by SENTISS PHARMA PRIVATE LIMITED. Status: granted. Granted Dec 31, 2019. Expires Dec 26, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SENTISS PHARMA PRIVATE LIMITED
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K31/498, A61K47/02, A61K47/186, A61K47/38, A61K9/0048
More from SENTISS PHARMA PRIVATE LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 10517869?
US 10517869 (Topical brimonidine tartrate ophthalmic solution) is held by SENTISS PHARMA PRIVATE LIMITED. Status: granted. Granted Dec 31, 2019. Expires Dec 26, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10517869?
SENTISS PHARMA PRIVATE LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 10517869 expire?
Our index shows an expiration date of Dec 26, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.